SCHEMBL16626410

SCHEMBL16626410

Cc1ccc(Nc2ccc3c(CN(C)C(=O)OC(C)(C)C)cn(S(=O)(=O)c4cccnc4)c3c2)c(F)c1

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 3/20 0.36
IDE P14735 1/20 0.35
PDE4A P27815 1/20 0.35
PDE4B Q07343 1/20 0.35
PDE4C Q08493 1/20 0.35
PDE4D Q08499 1/20 0.35
HDAC1 Q13547 2/20 0.34
HDAC2 Q92769 2/20 0.34
HDAC6 Q9UBN7 2/20 0.34
TNFSF11 O14788 2/20 0.34
FLT1 P17948 1/20 0.33
KDR P35968 1/20 0.33
POLB P06746 1/20 0.33
HTR6 P50406 3/20 0.33
HTT P42858 1/20 0.33
CYP19A1 P11511 1/20 0.32
FBP1 P09467 1/20 0.32
RORC P51449 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16626614 0.91 HTR6 (0.41) HDAC1HDAC2HDAC6TNFSF11HTR6
SCHEMBL16619211 0.90 TNFSF11 (0.38) NAMPTIDEPDE4APDE4BPDE4C
SCHEMBL16626507 0.89 HDAC1 (0.38) IDEHDAC1HDAC2HDAC6TNFSF11
SCHEMBL16626071 0.88 POLB (0.36) NAMPTFLT1KDRPOLBHTT
SCHEMBL17971587 0.87 HTR6 (0.34) IDEPDE4APDE4BPDE4CPDE4D
SCHEMBL16626756 0.84 IDE (0.33) NAMPTIDEHDAC1HDAC2HDAC6
SCHEMBL16626413 0.82 NAMPT (0.37) NAMPTIDEPDE4APDE4BPDE4C
SCHEMBL19971356 0.82 IDE (0.37) NAMPTIDEPDE4APDE4BPDE4C
SCHEMBL16626645 0.82 HTR6 (0.41) IDEPDE4APDE4BPDE4CPDE4D
Hydrochloric Acid SCHEMBL16619306 0.82 NAMPT (0.37) NAMPTIDEPDE4APDE4BPDE4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3052484-B1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAE WOONG PHARMA (KR) 2018-03-21 EP claimed
EP-3052484-B1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAE WOONG PHARMA (KR) 2018-03-21 EP disclosed
US-9676714-B2 Sulfonylindole derivatives and method for preparing the same DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2017-06-13 US disclosed
US-9676714-B2 Sulfonylindole derivatives and method for preparing the same DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2017-06-13 US disclosed
US-20160221946-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2016-08-04 US disclosed
US-20160221946-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2016-08-04 US disclosed
WO-2015050412-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2015-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160221946-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME GIPR, PGC, SI NAMPT 1610/4885IDE 2586/4885PDE4A 2460/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.